Centessa Pharmaceuticals Aktie

23,60 EUR +1,20 EUR +5,36 %

10.03.2026

BMN

27,58 USD +1,49 USD +5,71 %

10.03.2026

BTT

Centessa Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Div. Rendite0,00%

WKNA3CQ72

ISINUS1523091007

SymbolCNTA

Centessa Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

26.02.26MotleyFoolForget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline

13.11.25MotleyFoolWhy Centessa Pharmaceuticals Stock Crushed the Market Today

08.11.25finanzen.netCentessa Pharmaceuticals: Was beim Unternehmen in den jüngsten Büchern steht

WerbungCentessa Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

03.09.25TraderFoxKursziele

TOP-5-Kursziele der Analysten am 03.09.25

14.08.25finanzen.netCentessa Pharmaceuticals präsentierte das Zahlenwerk zum abgelaufenen Jahresviertel

21.07.25TraderFoxTrading-Sektionen

Centessa Pharmaceuticals (CNTA): Truist sieht 88 % Kurspotenzial - ORX750 bietet Potenzial bei Narkolepsie und idiopathischer Hypersomnie

21.07.25TraderFoxKursziele

TOP-5-Kursziele der Analysten am 21.07.25

16.06.25ZacksCentessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?

04.06.25ZacksWall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet

16.05.25finanzen.netCentessa Pharmaceuticals verkündete Quartalsergebnis zum jüngsten Jahresviertel

14.05.25GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

08.05.25BenzingaThis Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

26.03.25finanzen.netCentessa Pharmaceuticals vermeldete Zahlen zum jüngsten Quartal

24.03.25GlobeNewswireCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

14.11.24finanzen.netCentessa Pharmaceuticals: Bilanzvorlage zum letzten Quartal

12.11.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

13.09.24GlobeNewswireCentessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

11.09.24GlobeNewswireCentessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

10.09.24GlobeNewswireCentessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

27.08.24GlobeNewswireCentessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research

15.08.24finanzen.netCentessa Pharmaceuticals mit Zahlen zum abgelaufenen Quartal

13.08.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

15.05.24finanzen.netCentessa Pharmaceuticals: Quartalsergebnisse zum jüngsten Jahresviertel

13.05.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

24.04.24GlobeNewswireCentessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

23.04.24GlobeNewswireCentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

22.04.24GlobeNewswireCentessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

30.03.24finanzen.netCentessa Pharmaceuticals stellte Ergebnisse des abgelaufenen Quartals vor

28.03.24GlobeNewswireCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

10.12.23GlobeNewswireCentessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

14.11.23finanzen.netCentessa Pharmaceuticals gewährte Anlegern Blick in die Bücher

13.11.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

25.10.23GlobeNewswireCentessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

16.08.23finanzen.netCentessa Pharmaceuticals: So viel setzte das Unternehmen zuletzt um

14.08.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

10.07.23GlobeNewswireCentessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

24.05.23GlobeNewswireCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences

22.05.23GlobeNewswireCentessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

13.05.23finanzen.netCentessa Pharmaceuticals: Bilanzzahlen zum vergangenen Quartal

12.05.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

Centessa Pharmaceuticals News

Centessa Pharmaceuticals News: auf dieser Seite finden Sie alle Centessa Pharmaceuticals News und Nachrichten zur Centessa Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Centessa Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Centessa Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.